Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) reported financial results for the fourth quarter and full year 2025 that surpassed analyst expectations, driven by robust growth from its two flagship products. The company also provided initial revenue guidance for 2026 that appears conservative relative to current Wall Street forecasts.
Earnings and Revenue Highlights
The biopharmaceutical company delivered a significant beat on both the top and bottom lines for the final quarter of 2025.
- Q4 2025 Revenue: Reported at $152.6 million, exceeding the analyst consensus estimate of approximately $144.9 million.
- Q4 2025 Non-GAAP EPS: Came in at $0.68 per diluted share, nearly double the analyst estimate of $0.34.
- Full-Year 2025 Performance: Total revenues reached a record $589.0 million, representing 19.8% year-over-year growth. Non-GAAP net income for the year was $346.2 million, or $2.72 per diluted share.
The quarterly outperformance was fueled by the continued strong commercial execution of the company's promoted products. FIRDAPSE, its treatment for Lambert-Eaton myasthenic syndrome (LEMS), generated $97.6 million in Q4 net revenue, an 18.3% increase from the prior year. AGAMREE, for Duchenne muscular dystrophy, saw net revenue surge 67.5% year-over-year to $35.3 million, reflecting rapid market adoption since its launch.
Market Reaction and Outlook
Following the earnings release, the stock showed modest positive movement in after-hours trading, indicating a favorable but measured initial response from investors. This reaction likely balances the strong quarterly beat against the company's forward-looking guidance.
For the full year 2026, Catalyst issued total revenue guidance in a range of $615 million to $645 million. This forecast, which implies growth of 4.4% to 9.5% over 2025, sits notably below the current analyst consensus estimate of approximately $631.0 million for 2026 sales. The company's outlook is based on expected growth from its core franchises:
- FIRDAPSE 2026 Guidance: $435 - $450 million (21.4% - 25.6% growth)
- AGAMREE 2026 Guidance: $140 - $150 million (19.6% - 28.1% growth)
The guidance anticipates a steep decline for FYCOMPA, an anti-seizure medication facing generic competition, to between $40 million and $45 million. A key positive for future margins highlighted in the release is a significant reduction in royalty rates for FIRDAPSE, from a previous maximum of 18.5% down to 6% on U.S. net sales, effective January 2026.
Strategic and Operational Summary
Beyond the financial figures, the press release outlined several key business developments from 2025:
- The company continues to actively pursue business development, reviewing over 100 acquisition targets in 2025 with a focus on rare disease assets.
- A $200 million share repurchase program was initiated in Q4 2025, with approximately $39.9 million worth of shares already bought back.
- The company settled patent litigation for FIRDAPSE with Teva and Lupin, leaving one case pending against Hetero USA.
- Catalyst received several industry recognitions, including a spot on the Deloitte Technology Fast 500 and Forbes' list of America's Most Successful Small-Cap Companies.
The company ended the year with a strong balance sheet, holding $709.2 million in cash and cash equivalents.
For a detailed breakdown of future earnings estimates and historical performance, readers can review more information on the company's earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
